A randomised trial of a community pharmacist-initiated screening and intervention program for osteoporosis: the OsteoPharm Study

Completed

• Conditions: Osteoporosis; Musculoskeletal Diseases

• Registration Number: ISRCTN54746861
• Lead Sponsor: niversity of Alberta (Canada)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-01-26
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

Males or females who are:
1. Over the age of 50
2. Considered to be at a high risk for osteoporosis and fractures as defined by the Osteoporosis Society of Canada Clinical Practice guidelines and as defined specifically for the purposes of this study, i.e., are over the age of 65 years or between 50 - 64 years of age with any one of the following:
2.1. Family history of osteoporosis
2.2. Previous fragility fracture
2.3. Systemic steroids
2.4. Early menopause (for women)
3. Live in the Capital Health Region (Edmonton Region)

Exclusion Criteria

1. Are unable or unwilling to provide informed consent
2. Are on current prescription treatment for osteoporosis
3. Have had a dual energy x-ray absortiometry (DEXA) scan performed in the past two years
4. Are non-English speaking

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Composite endpoint of the performance of a bone mineral density test or a new prescription for an osteoporosis medication within four months of study entry.

Secondary Outcome Measures

Name	Time	Method
1. Each component of the primary outcome<br>2. Use of calcium and vitamin D supplements<br>3. Patient?s osteoporosis related knowledge using the Facts on Osteoporosis Quiz, (FoOQ)<br>4. Changes in generic health status (RAND-12)<br>5. Osteoporosis specific quality of life